Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Prostatic Neoplasms × Electroporation × Clear all

Phase

Status

Sponsor Class

OTHER 8 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Dysplasia 1 Triple Negative Breast Neoplasms 1 Squamous Intraepithelial Lesions 1 Prostatic Neoplasms 1 Melanoma 1 Liver Diseases 1 Carcinoma, Hepatocellular 1

Interventions

Prednisone 92 Docetaxel 66 enzalutamide 64 Abiraterone Acetate 62 Leuprolide 45 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 41 abiraterone 29 apalutamide 26 bicalutamide 23 Prednisolone 23 pembrolizumab 20 Zoledronic Acid 20 Goserelin 20 radium Ra 223 dichloride 19 darolutamide 19 cabazitaxel 15 Triptorelin Pamoate 14 sipuleucel-T 12 luprolide acetate gel depot 12 Androgen Antagonists 12 Dexamethasone 11 olaparib 10 Injections 10 gallium 68 PSMA-11 9 Pluvicto 9 Mitoxantrone 9 Ipilimumab 9 Cyclophosphamide 8 relugolix 7 orteronel 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04972097 2025-02-12

PRESERVE

Angiodynamics, Inc.

Phase NA Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡